betamethasone 17 valerate + disodium cromoglycate

This is a combination drug consisting of betamethasone 17 valerate, a potent synthetic glucocorticoid corticosteroid, and disodium cromoglycate (also known as sodium cromoglicate or cromolyn sodium), a mast cell stabilizer. Betamethasone 17 valerate acts primarily by binding to the glucocorticoid receptor and modulating gene expression to suppress inflammation and immune responses. Disodium cromoglycate prevents the degranulation of mast cells, thereby inhibiting the release of histamine and other mediators involved in allergic reactions. The combination has been studied for use in asthma management—particularly in children with severe perennial asthma not adequately controlled by either agent alone—and potentially for allergic rhinitis. However, studies indicate that while both drugs are effective individually, their combined use does not provide significant additional benefit over corticosteroid monotherapy[1][2][6]. Betamethasone 17 valerate is generally considered superior to disodium cromoglycate for controlling symptoms in severe cases[6].

Other names

betamethasone valerate + sodium cromoglycatebetamethasone 17-valerate + sodium cromoglycate